PMID- 18219758
OWN - NLM
STAT- MEDLINE
DCOM- 20080208
LR  - 20191027
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 55
IP  - 5
DP  - 2007 Sep-Oct
TI  - Dendritic/tumor fusion cell-based vaccination against cancer.
PG  - 281-7
AB  - A promising area of investigation is the use of cancer vaccines to eliminate 
      residual tumor cells. Dendritic cells (DCs) are potent professional 
      antigen-presenting cells able to induce primary immune responses. DCs capture and 
      process antigens into peptides and present them to T cells and B cells through 
      MHC class I and II molecules. An alternative approach to the induction of 
      antitumor immunity is the use of fusions of DCs and tumor cells. In this 
      approach, a broad spectrum of tumor-associated antigens, including those known 
      and unidentified, are processed endogenously and presented by MHC class I and II 
      pathways in the context of costimulatory signals. In animal studies, vaccination 
      with DC/tumor fusion cells results in the elimination of established lung 
      metastasis. Preclinical human studies have demonstrated that DC/tumor fusion 
      cells induce antigen-specific polyclonal cytotoxic T-lymphocyte responses against 
      autologous tumor in vitro. In clinical studies, vaccination of cancer patients 
      with autologous DC/tumor fusion cells is associated with immunological and 
      clinical responses in a subset of patients. Future studies should be investigated 
      to improve the immunogenicity of DC/tumor fusion cell preparations. This review 
      provides a general overview of the DC/tumor fusion cell-based vaccine and 
      summarizes some of the recent advances in this field.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan. shigeo_koido@jikei.ac.jp
FAU - Hara, Eiichi
AU  - Hara E
FAU - Homma, Sadamu
AU  - Homma S
FAU - Fujise, Kiyotaka
AU  - Fujise K
FAU - Gong, Jianlin
AU  - Gong J
FAU - Tajiri, Hisao
AU  - Tajiri H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Poland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*immunology/therapeutic use
MH  - Cell Fusion
MH  - Dendritic Cells/*immunology/transplantation
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasms/*immunology/pathology/*therapy
RF  - 58
EDAT- 2008/01/26 09:00
MHDA- 2008/02/09 09:00
CRDT- 2008/01/26 09:00
PHST- 2008/01/26 09:00 [pubmed]
PHST- 2008/02/09 09:00 [medline]
PHST- 2008/01/26 09:00 [entrez]
AID - 10.1007/s00005-007-0034-6 [doi]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2007 Sep-Oct;55(5):281-7. doi: 
      10.1007/s00005-007-0034-6.